肿瘤突变负荷对结直肠癌患者免疫治疗疗效的预测价值  

Value of tumor mutation burden in predicting efficiency of immunotherapy for patients with colorectal cancer

作　　者：张奥伦 殷婷[2] 张西志[2] ZHANG Aolun;YIN Ting;ZHANG Xizhi(Medical College of Yangzhou University,Yangzhou,Jiangsu,225009;Department of Oncology,Subei People′s Hospital Affiliated to Yangzhou University,Yangzhou,Jiangsu,225001)

机构地区：[1]扬州大学医学院,江苏扬州225009 [2]扬州大学附属苏北人民医院肿瘤科,江苏扬州225001

出　　处：《实用临床医药杂志》2020年第8期128-132,共5页Journal of Clinical Medicine in Practice

基　　金：吴阶平医学基金会资助项目(HX2019018)。

摘　　要：目前,结直肠癌的治疗已经从“外科为主、放化疗为辅”的固有治疗模式转向了精准化、个体化的治疗理念,免疫治疗越来越受到重视。然而,并不是所有的患者都对免疫检查点抑制剂有反应。因此,预测治疗反应的可能性将有助于对可获益的患者进行筛选。较多研究表明,肿瘤突变负荷与免疫检查点抑制剂的疗效呈正相关,可以成为免疫治疗的独立生物标记物。本研究对肿瘤突变负荷在结直肠癌患者免疫治疗疗效中的预测价值及应用现状进行综述。At present,the treatment of colorectal cancer has changed from the inherent treatment mode of"surgery as the main therapy,radiotherapy and chemotherapy as adjuvant therapy"to the precise and individualized treatment concept,and immunotherapy has been paid more and more attention.However,not all the patients respond to immunocheckpoint inhibitors.Therefore,predicting the possibility of treatment response will help to screen the patients who can benefit.Many studies have shown that tumor mutation load has a positive correlation with the efficacy of immunosuppressive checkpoint inhibitors,and it can become an independent biomarker of immunotherapy.In this study,the prediction value and application status of tumor mutation load in immunotherapy of patients with colorectal cancer were reviewed.

关 键 词：免疫治疗 免疫检查点 结直肠癌 肿瘤突变负荷 程序性死亡蛋白 微卫星稳定 

分 类 号：R735.3[医药卫生—肿瘤]